PT2943467T - Derivados de benzilidenoguanidina e utilização terapêutica para o tratamento de doenças devidas a desarranjo conformacional de proteína - Google Patents
Derivados de benzilidenoguanidina e utilização terapêutica para o tratamento de doenças devidas a desarranjo conformacional de proteínaInfo
- Publication number
- PT2943467T PT2943467T PT147003107T PT14700310T PT2943467T PT 2943467 T PT2943467 T PT 2943467T PT 147003107 T PT147003107 T PT 147003107T PT 14700310 T PT14700310 T PT 14700310T PT 2943467 T PT2943467 T PT 2943467T
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- therapeutic use
- protein misfolding
- misfolding diseases
- benzylideneguanidine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
- C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1300435.3A GB201300435D0 (en) | 2013-01-10 | 2013-01-10 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2943467T true PT2943467T (pt) | 2016-10-18 |
Family
ID=47757796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147003107T PT2943467T (pt) | 2013-01-10 | 2014-01-10 | Derivados de benzilidenoguanidina e utilização terapêutica para o tratamento de doenças devidas a desarranjo conformacional de proteína |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9682943B2 (pt) |
| EP (2) | EP3115357B1 (pt) |
| JP (1) | JP6276289B2 (pt) |
| KR (1) | KR102166665B1 (pt) |
| CN (1) | CN105189452B (pt) |
| AU (2) | AU2014204831C1 (pt) |
| CA (1) | CA2896976C (pt) |
| DK (1) | DK2943467T3 (pt) |
| ES (2) | ES2594378T3 (pt) |
| GB (1) | GB201300435D0 (pt) |
| HR (1) | HRP20161208T1 (pt) |
| HU (1) | HUE030848T2 (pt) |
| IL (1) | IL239629B (pt) |
| LT (1) | LT2943467T (pt) |
| MX (1) | MX370491B (pt) |
| PL (1) | PL2943467T3 (pt) |
| PT (1) | PT2943467T (pt) |
| RS (1) | RS55185B1 (pt) |
| RU (1) | RU2654910C2 (pt) |
| SI (1) | SI2943467T1 (pt) |
| WO (1) | WO2014108520A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
| US10905663B2 (en) | 2013-03-05 | 2021-02-02 | The University Of Chicago | Treatment of demyelinating disorders |
| KR102387615B1 (ko) * | 2014-07-02 | 2022-04-18 | 인플렉티스 바이오사이언스 | 단백질질환의 치료를 위한 벤질리덴구아니딘 유도체들의 신규한 치료적 용도 |
| CN107709291B (zh) | 2015-04-08 | 2021-03-12 | 医疗研究局 | 抑制剂及其应用 |
| US9501793B1 (en) * | 2015-06-04 | 2016-11-22 | Herofi, Inc. | Archetecture and associated methodology for data standardization and utilization in retail industry applications |
| AU2016304331B2 (en) * | 2015-07-31 | 2021-08-05 | Inflectis Bioscience | Method of treating cancer with a combination of benzylideneguanidine derivatives and chemotherapeutic agent. |
| US11166464B2 (en) * | 2017-03-06 | 2021-11-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Self-assembled active agents |
| JP2021529729A (ja) | 2018-05-09 | 2021-11-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｉ型ｉｆｎ依存性病態を処置するためのグアナベンズ又はその誘導体の使用 |
| CN113072467B (zh) * | 2021-03-24 | 2022-04-12 | 南方医科大学 | 含取代胍基衍生物及其在制备破骨细胞分化抑制剂上的应用 |
| WO2024105168A1 (en) | 2022-11-18 | 2024-05-23 | Inflectis Bioscience | Novel combinations useful for the treatments of als |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1223491A (en) * | 1967-10-13 | 1971-02-24 | American Home Prod | Guanidines |
| US3541218A (en) | 1969-06-18 | 1970-11-17 | Lilly Co Eli | Omicron-fluorobenzylaminoguanidine for diabetes |
| SE7607653L (sv) | 1976-07-05 | 1978-01-06 | Haessle Ab | Substituerade triazoler |
| AU664710B2 (en) * | 1991-08-27 | 1995-11-30 | Upjohn Company, The | A method for treatment of metabolic disorders |
| PT793646E (pt) * | 1994-11-23 | 2002-03-28 | Biovitrum Ab | Carboxilatos de aminoguanidina destinados ao tratamento de diabetes mellitus nao-insulinodependente |
| US6335339B1 (en) | 1998-01-13 | 2002-01-01 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| WO2001025192A1 (en) | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| US6518269B1 (en) | 2000-07-28 | 2003-02-11 | University Of Arizona Foundation | Cancer treatment |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| FR2812812B1 (fr) | 2000-08-08 | 2002-10-11 | Philippe Gorny | Medicament destine notamment a combattre les dysfonctions sexuelles |
| EP1687641A2 (en) * | 2003-09-25 | 2006-08-09 | Acadia Pharmaceuticals Inc. | Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
| CN1875271A (zh) * | 2003-09-25 | 2006-12-06 | 阿卡蒂亚药品公司 | 用神经肽ff受体2激动剂治疗神经痛 |
| EP1908464A1 (en) * | 2006-10-04 | 2008-04-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases |
| DE602006006578D1 (de) * | 2006-10-04 | 2009-06-10 | Agronomique Inst Nat Rech | Chlor enthaltende Guanabenz Derivate zur Behandlung von Prionerkrankungen |
| WO2008091681A2 (en) | 2007-01-23 | 2008-07-31 | Housey Gerard M | Theramutein modulators |
| WO2011039735A2 (en) | 2009-10-02 | 2011-04-07 | Consiglio Nazionale Delle Ricerche | Compounds with ddx3 inhibitory activity and uses thereof |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| ES2587232T3 (es) | 2010-07-20 | 2016-10-21 | Vestaron Corporation | Triazinas y pirimidinas insecticidas |
| WO2012048330A2 (en) * | 2010-10-08 | 2012-04-12 | The Mclean Hospital Corporation | Treatment of motor neuron disease |
| GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
-
2013
- 2013-01-10 GB GBGB1300435.3A patent/GB201300435D0/en not_active Ceased
-
2014
- 2014-01-10 CN CN201480004604.1A patent/CN105189452B/zh active Active
- 2014-01-10 SI SI201430063A patent/SI2943467T1/sl unknown
- 2014-01-10 HU HUE14700310A patent/HUE030848T2/hu unknown
- 2014-01-10 EP EP16172383.8A patent/EP3115357B1/en active Active
- 2014-01-10 ES ES14700310.7T patent/ES2594378T3/es active Active
- 2014-01-10 KR KR1020157019864A patent/KR102166665B1/ko active IP Right Grant
- 2014-01-10 CA CA2896976A patent/CA2896976C/en active Active
- 2014-01-10 DK DK14700310.7T patent/DK2943467T3/en active
- 2014-01-10 LT LTEP14700310.7T patent/LT2943467T/lt unknown
- 2014-01-10 US US14/760,350 patent/US9682943B2/en active Active
- 2014-01-10 WO PCT/EP2014/050422 patent/WO2014108520A1/en active Application Filing
- 2014-01-10 JP JP2015552060A patent/JP6276289B2/ja active Active
- 2014-01-10 PL PL14700310T patent/PL2943467T3/pl unknown
- 2014-01-10 AU AU2014204831A patent/AU2014204831C1/en active Active
- 2014-01-10 RS RS20160798A patent/RS55185B1/sr unknown
- 2014-01-10 PT PT147003107T patent/PT2943467T/pt unknown
- 2014-01-10 RU RU2015127827A patent/RU2654910C2/ru active
- 2014-01-10 ES ES16172383T patent/ES2831453T3/es active Active
- 2014-01-10 MX MX2015008977A patent/MX370491B/es active IP Right Grant
- 2014-01-10 EP EP14700310.7A patent/EP2943467B1/en active Active
-
2015
- 2015-06-25 IL IL239629A patent/IL239629B/en active IP Right Grant
-
2016
- 2016-09-21 HR HRP20161208TT patent/HRP20161208T1/hr unknown
-
2017
- 2017-03-23 US US15/467,613 patent/US10100020B2/en active Active
- 2017-12-05 AU AU2017272151A patent/AU2017272151B2/en active Active
-
2018
- 2018-08-31 US US16/119,445 patent/US10526297B2/en active Active
-
2019
- 2019-11-25 US US16/694,694 patent/US10954198B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274646A (en) | Integrated continuous production of medicinal substances from medical protein | |
| IL239629B (en) | History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins | |
| HK1219943A1 (zh) | 用於治療眼科疾病和障害的取代 -苯基丙胺衍生物 | |
| HK1211290A1 (en) | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| HK1222331A1 (zh) | 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途 | |
| EP2943189A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEMYELINATING DISEASES | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| HK1225385A1 (zh) | 用於治療呼吸病的雜芳基衍生物 | |
| IL245738A0 (en) | Oxindole derivatives, ways of their preparation and their therapeutic use in the treatment of ampk-related diseases | |
| EP2949651A4 (en) | SUBSTITUTED BENZOTHIAZOLES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF HUMAN DISEASES | |
| EP2945953A4 (en) | SUBSTITUTED TETRACYCLIC THIOPHONE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES | |
| IL249485A0 (en) | History of o-alkylbenzylideneguanidine and therapeutic use for the treatment of disorders associated with the accumulation of misfolded proteins | |
| ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
| HK1216881A1 (zh) | 用於治療病毒感染和另外的疾病的吡啶酮衍生物 | |
| HK1223041A1 (zh) | 匹多莫德用於治療炎症相關疾病的用途 | |
| HK1219654A1 (zh) | 用於治療眼科疾病和病症的方法 | |
| IL239078A0 (en) | Protein for use in the treatment of eye diseases | |
| EP2943593A4 (en) | DIAGNOSIS AND TREATMENT OF VIRUS DISEASES | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| TH1401006421A (th) | สารประกอบสำหรับการใช้ในการผลิตยาสำหรับการรักษาโรคผิวหนังที่ตอบสนองต่อสเตียรอยด์ |